| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000020615 |
| Receipt No. | R000023342 |
| Official scientific title of the study | Effects of an Inhibitor of Sodium-glucose Cotransporter 2 for Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease (NAFLD). |
| Date of disclosure of the study information | 2016/02/01 |
| Last modified on | 2017/07/21 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Effects of an Inhibitor of Sodium-glucose Cotransporter 2 for Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease (NAFLD). | |
| Title of the study (Brief title) | SGLT2 Inhibitor for T2DM with NAFLD. | |
| Region |
|
|
| Condition | ||||
| Condition | Patients of type 2 diabetes mellitus with nonalcoholic fatty liver disease (NAFLD). | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To evaluate the effects of adding canagliflozin, an inhibitor of sodium-glucose cotransporter 2,in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease(NAFLD). |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Hepatic fat fraction (HFF) by hepatic magnetic resonance imaging (MRI) after 6 or 12 months. |
| Key secondary outcomes | body weight, HbA1c, glucagon, type IV collagen, hyaluronic acid and NAFLD fibrosis score. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | canagliflozin100mg/day | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1: Type 2 diabetes
2: Patients with NAFLD diagnosed by clinical data 3: Patients provided with informed consent |
|||
| Key exclusion criteria | 1: Diabetic ketoacidosis and hyperosmolar hyperglycemic state
2: Insulin dependent diabetes 3: Before and after surgery and severe trauma 4: Taking excessive alcohol 5: Severe renal failure or undergoing hemodialysis 6: Proliferative diabetic retinopathy 7: Obvious orthostatic hypotension 8: Patient who cannot be ruled out other liver disease including viral hepatitis, autoimmune hepatitis, a drug-induced hepatitis. 9: Severe hepatic dysfunction 10: Malignant neoplasm 11: Women who have a possibility of pregnancy or is pregnant 12: Allergy to SGLT2 inhibitors, having a recent history of taking SGLT2 inhibitors 13: Patient who is suspected type 1 diabetes and other diabetes |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Mitsuko Inoue |
| Organization | Kitasato University School of Medicine. |
| Division name | Department of Endocrinology, Diabetes and Metabolism |
| Address | 1-15-1 Kitasato, Minami, Sagamihara, Kanagawa, Japan |
| TEL | 042-778-8111 |
| mitsuko_oku325@yahoo.co.jp | |
| Public contact | |
| Name of contact person | Mitsuko Inoue |
| Organization | Kitasato University School of Medicine. |
| Division name | Department of Endocrinology, Diabetes and Metabolism. |
| Address | 1-15-1 Kitasato, Minami, Sagamihara, Kanagawa, Japan. |
| TEL | 042-778-8111 |
| Homepage URL | |
| mitsuko_oku325@yahoo.co.jp | |
| Sponsor | |
| Institute | Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | nothing |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 北里大学病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000023342 |